Literature DB >> 17604130

Extension of the typing in a general-primer-PCR reverse-line-blotting system to detect all 25 cutaneous beta human papillomaviruses.

Ingo Nindl1, Anja Köhler, Marc Gottschling, Tobias Forschner, Mandy Lehmann, Chris J L M Meijer, Peter J F Snijders, Eggert Stockfleth.   

Abstract

beta-Papillomaviruses (PV) seem to be involved in the pathogenesis of cutaneous squamous cell carcinoma and its early stage actinic keratosis. In this study, typing was extended of a previously described consensus primer-mediated beta- and gamma-cutaneous HPV PCR method followed by reverse-line-blotting (BGC-PCR/RLB) to detect all 25 known beta-PV and to examine their prevalence in actinic keratosis. The typing format of the BGC-PCR assay was extended by adding hybridization probes of six beta-PV (HPV 75, 76, 80, 92, 93, and 96) to the RLB system. Subsequently, tumor and normal skin tissues were collected from 75 patients with actinic keratosis, allowing typing for a total of 25 beta- and 5 gamma-types. The analytical sensitivity was between 10 copies (HPV 75, 80, 92, 93, and 96) and 100 copies (HPV 76). Except for that of HPV 76, none of the added probes showed any cross-hybridization with other beta-HPV. HPV DNA was detected in 45% of actinic keratosis and in 33% of normal skin by BGC-PCR, and at least one of the six added beta-types was present in 19% of actinic keratoses and in 13% of normal skin. Six beta-HPV types were added successfully to the typing format of the BGC-PCR/RLB system. The potential role of these types in the development of non-melanoma skin cancer awaits further studies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604130     DOI: 10.1016/j.jviromet.2007.05.022

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Quantification of beta-human papillomavirus DNA by real-time PCR.

Authors:  Sönke J Weissenborn; Ulrike Wieland; Monika Junk; Herbert Pfister
Journal:  Nat Protoc       Date:  2010-01       Impact factor: 13.491

Review 2.  Cutaneous squamous cell carcinoma and human papillomavirus: is there an association?

Authors:  Bishr Aldabagh; Jorge Gil C Angeles; Adela R Cardones; Sarah T Arron
Journal:  Dermatol Surg       Date:  2012-08-28       Impact factor: 3.398

3.  Validation of a diagnostic microarray for human papillomavirus: coverage of 102 genotypes.

Authors:  Sarah Tuttleton Arron; Peter Skewes-Cox; Phong H Do; Eric Dybbro; Maria Da Costa; Joel M Palefsky; Joseph L Derisi
Journal:  J Nucleic Acids       Date:  2011-05-18

Review 4.  Human papillomavirus in head and neck cancer.

Authors:  Anna Rosa Garbuglia
Journal:  Cancers (Basel)       Date:  2014-08-18       Impact factor: 6.639

Review 5.  Epidemiology and biology of cutaneous human papillomavirus.

Authors:  Emily M Nunes; Valéria Talpe-Nunes; Laura Sichero
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

6.  Detection of Alpha, Beta, Gamma, and Unclassified Human Papillomaviruses in Cervical Cancer Samples From Mexican Women.

Authors:  María Guadalupe Flores-Miramontes; Dominik Olszewski; Cristina Artaza-Irigaray; Anouk Willemsen; Ignacio G Bravo; Verónica Vallejo-Ruiz; Yelda Aurora Leal-Herrera; Patricia Piña-Sánchez; Andrea Molina-Pineda; Juan Carlos Cantón-Romero; María Guadalupe Martínez-Silva; Luis Felipe Jave-Suárez; Adriana Aguilar-Lemarroy
Journal:  Front Cell Infect Microbiol       Date:  2020-06-09       Impact factor: 5.293

Review 7.  Epidemiology and Burden of Human Papillomavirus and Related Diseases, Molecular Pathogenesis, and Vaccine Evaluation.

Authors:  Arnaud John Kombe Kombe; Bofeng Li; Ayesha Zahid; Hylemariam Mihiretie Mengist; Guy-Armel Bounda; Ying Zhou; Tengchuan Jin
Journal:  Front Public Health       Date:  2021-01-20

8.  Eyebrow hairs from actinic keratosis patients harbor the highest number of cutaneous human papillomaviruses.

Authors:  Ines Schneider; Mandy D Lehmann; Vlada Kogosov; Eggert Stockfleth; Ingo Nindl
Journal:  BMC Infect Dis       Date:  2013-04-24       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.